11 hours Eli Lilly: Still Much Room To Ride The Weight-Loss Wave Seeking Alpha Eli Lilly: Still Much Room To Ride The Weight-Loss Wave. Eli Lilly (LLY) X
2 days Medicare can cover Zepbound for sleep apnea, creating a significant opportunity for Eli Lilly MarketWatch X
2 days Flynn: Eli Lilly could capture a significant part of a $100 billion market with Zepbound. YouTube X
5 days Novo Nordisk Vs. Eli Lilly: Obesity Makes Their Future Bright, But One Of Them Has More Potential Seeking Alpha X
1 week Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know Zacks X
3 weeks Eli Lilly, Novo Nordisk Stocks Rise. Only One Is Operating From a Position of Strength. Yahoo Finance X
3 weeks Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark. Yahoo Finance X
3 weeks Eli Lilly’s Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive? Investor's Business Daily X
3 weeks Stocks on the Move: Uber, Carmax, Novo Nordisk, Eli Lilly, Merck, Crown Castle and Accenture YouTube X
3 weeks Eli Lilly: Improved Competitive Position In Obesity Market, But Strong Execution Is A Must Now Seeking Alpha X
3 weeks IBD 50’s Hims & Hers Tumbles After FDA Pulls Lilly’s Weight-Loss Drug From Shortage List Investor's Business Daily X
3 weeks Zealand Pharma And Eli Lilly: Strategic Focus On Weight Management And Future Outlook Seeking Alpha X
4 weeks Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf? Investor's Business Daily X
1 month Ro to offer lower-price vials of weight loss drug Zepbound by teaming up with Eli Lilly CNBC X
1 month Eli Lilly to test obesity drugs to treat addiction in 2025, CEO says #shorts #weightloss #zepbound YouTube X
1 month The Zacks Analyst Blog Highlights Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group Zacks X
Stock Market News